Inversago Pharma

About:

Inversago Pharma is a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists

Website: https://inversago.com/en/

Top Investors: Fonds de solidarité FTQ, New Enterprise Associates, adMare Bio Innovations, Amorchem, Forbion Capital Partners

Description:

Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions.